相关实验视频

Updated: May 20, 2025

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

在KRAS驱动的癌症中设计和结构优化新型SOS1抑制剂

Yating Chen¹, Qiupei Liu², Xianghui Meng³

¹State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang 550014, China.

Bioorganic & medicinal chemistry letters

|May 18, 2025

概括

一种新的SOS1抑制剂,化合物10i,与现有的治疗方法相比,对KRAS驱动的癌症表现出更高的疗效. 这种新的候选药物显示出增强的溶解性,并降低了关键癌症信号通路的调节.

科学领域:

在瘤学瘤学.
药用化学医学化学
分子生物学分子生物学

背景情况:

准SOS1,一个关氨酸核酸交换因子,是KRAS驱动癌症的一个有希望的策略.
药物耐药性的增加需要开发新的SOS1抑制剂,因为它们与现有的类似物具有结构上的相似性.

研究的目的:

发现和表征一种新的SOS1抑制剂,具有改善治疗KRAS驱动癌症的特性.
评估一种新型的帕拉-狄米甲基氨基胺基纳林支架抑制剂的临床前疗效和可溶性.

主要方法:

新型SOS1抑制剂的合成,利用一个对二甲基氨基胺基因纳林支架.
试验室试验包括KRASG12C::SOS1蛋白与蛋白相互作用 (PPI) 抑制和3D癌细胞增殖试验.
在生理pH下对水溶性的评估和在NCI-H358细胞中对下游信号标记物 (p-ERK,p-AKT) 的西方斑点分析.

主要成果:

在PPI和扩散试验中,具有新型支架的化合物10i与已知的SOS1抑制剂Hit1相比表现出更高的活性.
化合物10i在pH值6.8时显示出增强的水溶性.
用10i化合物治疗导致NCI-H358癌细胞中酸化ERK和AKT的下调.

结论:

化合物10i代表了对KRAS驱动的癌症有前途的候选药物.
化合物10i的新型支架和改进的特性为克服现有的耐药性提供了潜在的解决方案.
对化合物10i进行进一步的研究是有必要的,因为它在瘤学中的临床开发.

关键词:

在KRAS突变中发生突变.电阻电阻电阻电阻电阻电阻这是一种SOS1抑制剂.这就是SOS1-KRAS相互作用.

更多相关视频

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

Published on: September 5, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...